Welcome to the PharmaSource podcast: the pharma and biotech podcast that explores the latest trends, challenges, and commercial opportunities shaping the biopha...
Pharma's $300bn Revenue Gap: Horizon Scanning with L.E.K.
The pharmaceutical industry faces a significant challenge with patent expiries threatening established revenue streams of approximately $300 Billion USD.
Major brands are approaching patent expiry creating urgency for companies to identify new blockbuster opportunities. This is compounded by policy changes like the Inflation Reduction Act, which offers different exclusivity periods for biologics versus small molecules.
Adam Siebert and Jeff Holder are partners at L.E.K. Consulting’s life science enablers practice, specialising in biopharma manufacturing and supply chain strategy. With backgrounds spanning operations, services, and drug discovery, they help pharmaceutical companies and CDMOs navigate emerging technology trends.
In the latest episode of the PharmaSource podcast, Adam and Jeff shared insights on horizon scanning – the critical practice of forecasting drug development and manufacturing trends years in advance. Their discussion revealed key strategies for pharmaceutical companies and contract manufacturers to stay ahead of industry shifts.
Read the PharmaSource Interview
--------
22:04
Be ‘Right First Time’: Lessons for Biotech CMC with David Caron, Immunome’s SVP CMC
David Caron, Senior Vice-President of CMC, AL102 at Immunome, shares why choosing the right CDMO partner can make or break a biotech’s development timeline: “For biotechs, the main business challenge is to do right the first time. To do this, we need to look at the risks related to each activity.”
David Caron brings over three decades of pharmaceutical industry experience across multiple biotechs, with expertise spanning from bench formulation to senior leadership roles. His background includes extensive work with various dosage forms and regulatory requirements across EU and US markets.
In this latest episode of the PharmaSource podcast David shares crucial insights on how emerging biotechs can optimize their CDMO partnerships, manage costs effectively, and align CMC strategy with business objectives.
David Caron will be sharing advice about how to overcome biotech CMC challenges at CDMO Live 2025. Book your ticket here
Read the interview here
--------
30:03
From Platform to Product Development: Integra Therapeutics’ CEO on Scaling Gene Editing
Dr. Avencia Sánchez-Mejías is CEO and co-founder of Integra Therapeutics, a Barcelona-based biotech company developing next-generation gene-editing tools. With a background in molecular biology and clinical genetics, she brings over 15 years of experience in genetic therapy research across Europe, the US, and Asia.
In this exclusive interview, Avencia shares insights on transitioning from academia to entrepreneurship, building a sustainable biotech company, and leveraging strategic partnerships to bring innovative gene therapy solutions to market.
“Having a technology that can address genetic conditions and new diseases that today are not treatable, can have a huge impact. Not only for the patient but also for the cost of the health system.”, she says.
One of Integra’s most significant strategic decisions was expanding beyond being purely a platform technology company to developing their own therapeutic products. This transition required careful consideration of sustainable growth and market validation strategies.
“This is probably one of the most strategic decisions that we had to take,” Avencia explains. “We think hard and long on which first indication should be to be successful. It also changed the type of company that we were. We were very technological, and now we are building therapeutic products. So the kind of talent that you need also changes.”
Read full article
--------
20:54
ADC Manufacturing: Are only 5 CDMOs fit for purpose?
"The reality is, we have a lot of CDMOs don't they really know what they're getting into" says Herman Bozenhardt
Herman Bozenhardt, a pharmaceutical manufacturing consultant with decades of experience in facility design and operations, brings a wealth of knowledge from his work with numerous pharmaceutical companies and contract manufacturers. His expertise spans from traditional small molecule drugs to complex biologics and potent compounds.
In the latest PharmaSource podcast episode, Herman shares his candid thoughts on the challenges facing the pharmaceutical manufacturing industry, particularly in the rapidly growing field of Antibody-Drug Conjugates (ADCs). He explains why many Contract Development and Manufacturing Organizations (CDMOs) may not be adequately prepared to handle these complex and potent compounds.
https://pharmasource.global/content/podcast/adc-manufacturing-why-herman-bozenhardt-believes-only-5-cdmos-are-fit-for-purpose/
--------
37:16
GLP 1s and the Unintended Consequences of the $100 Billion Market
GLP-1 drugs have become a game-changer in treating obesity and type 2 diabetes, forecast to reach a $100 billion market value by 2029.
However, their rapid rise raises important questions about resource allocation in pharmaceutical development and manufacturing, as well as affecting the dynamics between patients, healthcare providers, and biopharma.
In the latest episode of the PharmaSource podcast, Ben Locwin, Chief Scientist at Black Diamond Networks, explains that GLP-1 drugs represent a significant breakthrough in the treatment of obesity and diabetes and the unintended consequences they are bringing to the industry.
Read the article here
Welcome to the PharmaSource podcast: the pharma and biotech podcast that explores the latest trends, challenges, and commercial opportunities shaping the biopharma outsourcing.
In each episode we'll be speaking with top executives, researchers, and outsourcing experts, who share their perspectives on topics such as building a smarter, more sustainable supply chain, how to partner with CDMOs, digital transformation, procurement and external manufacturing strategies, and plenty more besides.
Make sure to subscribe for your regular dose of pharma insight.